Alembic Pharmaceuticals Q4 FY25 Investor Presentation 2025

Alembic Pharmaceuticals reported Q4 FY25 revenue of INR 17.70 billion with 8% YoY growth and 16.15% EBITDA margin. Key segments showed strong performance: India Branded Business grew 20% YoY, US Generics surged 43% YoY, while Ex-US Generics recovered with 4% growth. The company maintains R&D investment at 9% of sales with net profit margin of 8.9%.